Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes

Yu Akazawa, Daisuke Nobuoka, Mari Takahashi, Toshiaki Yoshikawa, Manami Shimomura, Shoichi Mizuno, Toshiyoshi Fujiwara, Yasunari Nakamoto, Tetsuya Nakatsura

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Human lymphocyte antigen (HLA) class I molecules play a central role in cytotoxic T lymphocytes (CTL)-based antitumor immunity. However, the expression rate of HLA class I in cancer cells remains a topic of discussion. We compared HLA class I expression levels between cancer cells and surrounding non–tumorous hepatocytes in 20 early-stage hepatocellular carcinoma (HCC) patients by immunohistochemistry using EMR 8-5. The expression levels of HLA class I were classified as negative, incomplete positive or complete positive. Similarly, for various types of solid cancers, HLA class I expression was examined. For the HLA class I expression in cancer cells, among 20 HCC patients, 13 were complete positive, 3 were incomplete positive, and 4 were negative. In addition, 15 (75.0%) had higher expression levels of HLA class I in cancer cells compared with that in surrounding non–tumorous hepatocytes. An interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT) assay indicated that cancer cells with positive expression of HLA class I had strong sensitivity to antigen-specific CTL. We suggested that HLA class I expression in cancer cells could be involved in the clinical prognosis of HCC patients. Similarly, 66.7%, 100.0%, 66.7% and 62.5% of patients with early-stage pancreatic, gallbladder, esophageal and breast cancers, respectively, had higher expression levels of HLA class I in cancer cells than in surrounding normal tissue cells. We suggest that in several early-stage solid cancers, including HCC, HLA class I expression levels in cancer cells are higher than that in surrounding normal tissue cells, which could result in the anti–tumor effect of CTL-based cancer immunotherapy.

Original languageEnglish
Pages (from-to)1842-1852
Number of pages11
JournalCancer Science
Volume110
Issue number6
DOIs
Publication statusPublished - Jun 2019

Keywords

  • EMR 8-5 antibody
  • cytotoxic T lymphocytes
  • hepatocellular carcinoma
  • human lymphocyte antigen class I expression
  • immunohistochemistry

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes'. Together they form a unique fingerprint.

  • Cite this

    Akazawa, Y., Nobuoka, D., Takahashi, M., Yoshikawa, T., Shimomura, M., Mizuno, S., Fujiwara, T., Nakamoto, Y., & Nakatsura, T. (2019). Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes. Cancer Science, 110(6), 1842-1852. https://doi.org/10.1111/cas.14022